{"protocolSection": {"identificationModule": {"nctId": "NCT00446511", "orgStudyIdInfo": {"id": "CVAL489K2302E1"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension", "officialTitle": "An Extension to Study Protocol CVAL489K2302 to Evaluate the Long Term Safety, Tolerability and Efficacy of Valsartan in Children 6 to 17 Years of Age With Hypertension, Versus Enalapril Treatment for 14 Weeks, or Combined With Enalapril Versus Enalapril for 66 Weeks in Chronic Kidney Disease Patients."}, "statusModule": {"statusVerifiedDate": "2011-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-06"}, "primaryCompletionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-03-09", "studyFirstSubmitQcDate": "2007-03-09", "studyFirstPostDateStruct": {"date": "2007-03-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-11", "resultsFirstSubmitQcDate": "2011-05-02", "resultsFirstPostDateStruct": {"date": "2011-06-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-06-30", "lastUpdatePostDateStruct": {"date": "2011-07-12", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this extension study is to compare the long-term safety of valsartan versus enalapril, and the effectiveness of the combination of valsartan and enalapril versus enalapril alone in children with hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["children", "pediatrics", "high blood pressure", "hypertension", "valsartan", "enalapril"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 250, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "CKD patients: Valsartan+enalapril", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Valsartan", "Drug: Enalapril"]}, {"label": "CKD patients: Enalapril", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Enalapril", "Drug: placebo matched to valsartan"]}, {"label": "Non-CKD patients: Valsartan", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Valsartan", "Drug: placebo matched to enalapril"]}, {"label": "Non-CKD patients: Enalapril", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Enalapril", "Drug: placebo matched to valsartan"]}], "interventions": [{"type": "DRUG", "name": "Valsartan", "description": "Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.", "armGroupLabels": ["CKD patients: Valsartan+enalapril", "Non-CKD patients: Valsartan"]}, {"type": "DRUG", "name": "Enalapril", "description": "Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.", "armGroupLabels": ["CKD patients: Enalapril", "CKD patients: Valsartan+enalapril", "Non-CKD patients: Enalapril"]}, {"type": "DRUG", "name": "placebo matched to enalapril", "description": "Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.", "armGroupLabels": ["Non-CKD patients: Valsartan"]}, {"type": "DRUG", "name": "placebo matched to valsartan", "description": "placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.", "armGroupLabels": ["CKD patients: Enalapril", "Non-CKD patients: Enalapril"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Patients With Adverse Events", "timeFrame": "Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients)"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.", "timeFrame": "Core Baseline (Week 0) to Week 26"}, {"measure": "Percentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26", "description": "Systolic and diastolic blood pressure (BP) control was defined as msSBP and msDBP \\< 95th percentile for gender, age, and height. After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.", "timeFrame": "Week 26"}, {"measure": "Change From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20", "description": "24-hour ambulatory blood pressure monitoring (ABPM) was conducted once during the extension in a subset of patients at selected centers. For all patients who completed a qualifying ABPM at baseline, an ABPM was to be performed at Week 20. The ABPM monitor was placed on the non-dominant arm.", "timeFrame": "Core Baseline (Week 0) to Week 20"}, {"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.", "timeFrame": "Core Baseline (Week 0) to Week 26"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Successful completion of 12 weeks of double-blind treatment in core protocol CVAL489K2302.\n* Patients participating in study CVAL489K2302 who may have discontinued prematurely due to uncontrolled hypertension defined as MSSBP \\> 20%, but \\< 25% above the 95th percentile for age, gender, and height after visit 5, qualifies a patient for entry into this extension study.\n\nExclusion Criteria:\n\n* Renal artery stenosis.\n* Current diagnosis of heart failure (NYHA Class II-IV).\n* Second or third degree heart block without a pacemaker.\n* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.\n* Clinically significant valvular heart disease.\n* Patient that demonstrates clinically significant ECG abnormalities other than those associated with left ventricular hypertrophy and AV block controlled with a pacemaker.\n* Previous solid organ transplantation except renal, liver or heart transplantation. Renal, liver or heart transplant must have occurred at least 6 months prior to enrollment. Patient must be on stable doses of immunosuppressive therapy for 3 months and deemed clinically stable by the investigator.\n* Patients who experienced any adverse events considered serious and drug related in protocol CVAL489K2302.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Sites in USA", "city": "East Hanover", "state": "New Jersey", "zip": "07936", "country": "United States", "geoPoint": {"lat": 40.8201, "lon": -74.36487}}, {"facility": "Sites in Belgium", "city": "Belgium", "country": "Belgium"}, {"facility": "Sites in France", "city": "France", "country": "France"}, {"facility": "Sites in Germany", "city": "Germany", "country": "Germany"}, {"facility": "Sites in Hungary", "city": "Hungary", "country": "Hungary"}, {"facility": "Sites in India", "city": "India", "country": "India"}, {"facility": "Sites in Italy", "city": "Italy", "country": "Italy"}, {"facility": "Sites in Poland", "city": "Poland", "country": "Poland"}, {"facility": "Sites in Turkey", "city": "Turkey", "country": "Turkey"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "CKD Patients: Valsartan+Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to valsartan in the core study received combination therapy of valsartan and enalapril in the extension: Valsartan+enalapril (80/10, 160/20, 320/40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "FG001", "title": "CKD Patients: Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to enalapril in the core study received enalapril and valsartan placebo in the extension: Enalapril (10, 20, 40, weight stratified) and matching placebo to valsartan (80, 160, 320 mg). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "FG002", "title": "Non-CKD Patients: Valsartan", "description": "Non-chronic kidney disease (CKD) patients assigned to valsartan in the core study continued their valsartan monotherapy treatment in the extension: Valsartan (80, 160, 320 mg, weight stratified)+enalapril placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "FG003", "title": "Non-CKD Patients: Enalapril", "description": "Non-chronic kidney disease (CKD) patients assigned to enalapril in the core study continued their enalapril monotherapy treatment in the extension: Enalapril (10, 20, 40, weight stratified)+valsartan placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "21"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "103"}, {"groupId": "FG003", "numSubjects": "109"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "96"}, {"groupId": "FG003", "numSubjects": "103"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Administrative Problems", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "CKD Patients: Valsartan+Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to valsartan in the core study received combination therapy of valsartan and enalapril in the extension: Valsartan+enalapril (80/10, 160/20, 320/40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "BG001", "title": "CKD Patients: Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to enalapril in the core study received enalapril and valsartan placebo in the extension: Enalapril (10, 20, 40, weight stratified) and matching placebo to valsartan (80, 160, 320 mg). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "BG002", "title": "Non-CKD Patients: Valsartan", "description": "Non-chronic kidney disease (CKD) patients assigned to valsartan in the core study continued their valsartan monotherapy treatment in the extension: Valsartan (80, 160, 320 mg, weight stratified)+enalapril placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "BG003", "title": "Non-CKD Patients: Enalapril", "description": "Non-chronic kidney disease (CKD) patients assigned to enalapril in the core study continued their enalapril monotherapy treatment in the extension: Enalapril (10, 20, 40, weight stratified)+valsartan placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "103"}, {"groupId": "BG003", "value": "109"}, {"groupId": "BG004", "value": "250"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.4", "spread": "3.40"}, {"groupId": "BG001", "value": "12.1", "spread": "3.07"}, {"groupId": "BG002", "value": "13.1", "spread": "2.75"}, {"groupId": "BG003", "value": "13.3", "spread": "2.81"}, {"groupId": "BG004", "value": "13.0", "spread": "2.89"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "41"}, {"groupId": "BG003", "value": "27"}, {"groupId": "BG004", "value": "81"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "82"}, {"groupId": "BG004", "value": "169"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Patients With Adverse Events", "populationDescription": "Extension safety population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients)", "groups": [{"id": "OG000", "title": "CKD Patients: Valsartan+Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to valsartan in the core study received combination therapy of valsartan and enalapril in the extension: Valsartan+enalapril (80/10, 160/20, 320/40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG001", "title": "CKD Patients: Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to enalapril in the core study received enalapril and valsartan placebo in the extension: Enalapril (10, 20, 40, weight stratified) and matching placebo to valsartan (80, 160, 320 mg). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG002", "title": "Non-CKD Patients: Valsartan", "description": "Non-chronic kidney disease (CKD) patients assigned to valsartan in the core study continued their valsartan monotherapy treatment in the extension: Valsartan (80, 160, 320 mg, weight stratified)+enalapril placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG003", "title": "Non-CKD Patients: Enalapril", "description": "Non-chronic kidney disease (CKD) patients assigned to enalapril in the core study continued their enalapril monotherapy treatment in the extension: Enalapril (10, 20, 40, weight stratified)+valsartan placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "103"}, {"groupId": "OG003", "value": "109"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "51"}, {"groupId": "OG003", "value": "53"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to Week 26", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.", "populationDescription": "Extension ITT population: All patients that had both baseline and at least 1 post-Week 12 assessment of any efficacy variable (sitting systolic/diastolic BP) during the extension. Baseline is the Week 0 value. Extension endpoint is the Week 26 or last observation after the core endpoint but before Week 26 carried forward value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Core Baseline (Week 0) to Week 26", "groups": [{"id": "OG000", "title": "CKD Patients: Valsartan+Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to valsartan in the core study received combination therapy of valsartan and enalapril in the extension: Valsartan+enalapril (80/10, 160/20, 320/40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG001", "title": "CKD Patients: Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to enalapril in the core study received enalapril and valsartan placebo in the extension: Enalapril (10, 20, 40, weight stratified) and matching placebo to valsartan (80, 160, 320 mg). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG002", "title": "Non-CKD Patients: Valsartan", "description": "Non-chronic kidney disease (CKD) patients assigned to valsartan in the core study continued their valsartan monotherapy treatment in the extension: Valsartan (80, 160, 320 mg, weight stratified)+enalapril placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG003", "title": "Non-CKD Patients: Enalapril", "description": "Non-chronic kidney disease (CKD) patients assigned to enalapril in the core study continued their enalapril monotherapy treatment in the extension: Enalapril (10, 20, 40, weight stratified)+valsartan placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "103"}, {"groupId": "OG003", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.4", "spread": "11.48"}, {"groupId": "OG001", "value": "-11.7", "spread": "9.55"}, {"groupId": "OG002", "value": "-7.5", "spread": "8.47"}, {"groupId": "OG003", "value": "-7.2", "spread": "8.99"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Non-CKD Patients Achieving Systolic and Diastolic BP Control at Week 26", "description": "Systolic and diastolic blood pressure (BP) control was defined as msSBP and msDBP \\< 95th percentile for gender, age, and height. After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.", "populationDescription": "The extension ITT population consisted of all extension patients that had both baseline and at least one post-Week 12 assessment of any efficacy variable (sitting systolic/diastolic blood pressure) during the extension. Patients were analyzed according to the treatment they were assigned to at the beginning of their extension.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Non-CKD Patients: Valsartan", "description": "All non-CKD patients assigned to valsartan in the core study (CVAL489K2302) continued their monotherapy treatment of valsartan 80/160/320 mg stratified by weight."}, {"id": "OG001", "title": "Non-CKD Patients: Enalapril", "description": "All non-CKD patients assigned to enalapril in the core study (CVAL489K2302) continued their monotherapy treatment of enalapril 10/20/40 mg stratified by weight."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "103"}, {"groupId": "OG001", "value": "108"}]}], "classes": [{"title": "Systolic BP control", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.0"}, {"groupId": "OG001", "value": "63.0"}]}]}, {"title": "Diastolic BP control", "categories": [{"measurements": [{"groupId": "OG000", "value": "95.1"}, {"groupId": "OG001", "value": "91.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Post-dosing 24-hour Mean Systolic and Diastolic Ambulatory Blood Pressure at Week 20", "description": "24-hour ambulatory blood pressure monitoring (ABPM) was conducted once during the extension in a subset of patients at selected centers. For all patients who completed a qualifying ABPM at baseline, an ABPM was to be performed at Week 20. The ABPM monitor was placed on the non-dominant arm.", "populationDescription": "ABPM population: All ITT patients who received the 24-hour ambulatory blood pressure monitoring (ABPM) measurements at both baseline and Week 20. Patients were excluded if their baseline ABPM was measured after active treatment dose (considered invalid baseline).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Core Baseline (Week 0) to Week 20", "groups": [{"id": "OG000", "title": "CKD Patients: Valsartan+Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to valsartan in the core study received combination therapy of valsartan and enalapril in the extension: Valsartan+enalapril (80/10, 160/20, 320/40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG001", "title": "CKD Patients: Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to enalapril in the core study received enalapril and valsartan placebo in the extension: Enalapril (10, 20, 40, weight stratified) and matching placebo to valsartan (80, 160, 320 mg). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG002", "title": "Non-CKD Patients: Valsartan", "description": "Non-chronic kidney disease (CKD) patients assigned to valsartan in the core study continued their valsartan monotherapy treatment in the extension: Valsartan (80, 160, 320 mg, weight stratified)+enalapril placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG003", "title": "Non-CKD Patients: Enalapril", "description": "Non-chronic kidney disease (CKD) patients assigned to enalapril in the core study continued their enalapril monotherapy treatment in the extension: Enalapril (10, 20, 40, weight stratified)+valsartan placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "10"}, {"groupId": "OG003", "value": "21"}]}], "classes": [{"title": "Systolic BP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-23.3", "spread": "11.60"}, {"groupId": "OG001", "value": "-0.3", "spread": "14.42"}, {"groupId": "OG002", "value": "-11.5", "spread": "7.81"}, {"groupId": "OG003", "value": "-4.1", "spread": "11.49"}]}]}, {"title": "Diastolic BP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.8", "spread": "3.20"}, {"groupId": "OG001", "value": "2.9", "spread": "10.81"}, {"groupId": "OG002", "value": "-12.2", "spread": "6.60"}, {"groupId": "OG003", "value": "-4.5", "spread": "7.59"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to Week 26", "description": "After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using a calibrated standard sphygmomanometer and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. A negative number indicates lowered blood pressure.", "populationDescription": "Extension ITT population: All patients that had both baseline and at least 1 post-Week 12 assessment of any efficacy variable (sitting systolic/diastolic BP) during the extension. Baseline is the Week 0 value. Extension endpoint is the Week 26 or last observation after the core endpoint but before Week 26 carried forward value.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Core Baseline (Week 0) to Week 26", "groups": [{"id": "OG000", "title": "CKD Patients: Valsartan+Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to valsartan in the core study received combination therapy of valsartan and enalapril in the extension: Valsartan+enalapril (80/10, 160/20, 320/40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG001", "title": "CKD Patients: Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to enalapril in the core study received enalapril and valsartan placebo in the extension: Enalapril (10, 20, 40, weight stratified) and matching placebo to valsartan (80, 160, 320 mg). All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG002", "title": "Non-CKD Patients: Valsartan", "description": "Non-chronic kidney disease (CKD) patients assigned to valsartan in the core study continued their valsartan monotherapy treatment in the extension: Valsartan (80, 160, 320 mg, weight stratified)+enalapril placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}, {"id": "OG003", "title": "Non-CKD Patients: Enalapril", "description": "Non-chronic kidney disease (CKD) patients assigned to enalapril in the core study continued their enalapril monotherapy treatment in the extension: Enalapril (10, 20, 40, weight stratified)+valsartan placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "103"}, {"groupId": "OG003", "value": "108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-23.6", "spread": "10.79"}, {"groupId": "OG001", "value": "-18.2", "spread": "9.51"}, {"groupId": "OG002", "value": "-11.6", "spread": "9.74"}, {"groupId": "OG003", "value": "-10.2", "spread": "9.70"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Start of extension (week 13) to end of study (Week 26 in non-CKD patients and Week 50 in CKD patients).", "eventGroups": [{"id": "EG000", "title": "CKD Patients: Valsartan+Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to valsartan in the core study received combination therapy of valsartan and enalapril in the extension: Valsartan+enalapril (80/10, 160/20, 320/40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.", "seriousNumAffected": 7, "seriousNumAtRisk": 21, "otherNumAffected": 14, "otherNumAtRisk": 21}, {"id": "EG001", "title": "Non-CKD Patients: Valsartan", "description": "Non-chronic kidney disease (CKD) patients assigned to valsartan in the core study continued their valsartan monotherapy treatment in the extension: Valsartan (80, 160, 320 mg, weight stratified)+enalapril placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food.", "seriousNumAffected": 1, "seriousNumAtRisk": 103, "otherNumAffected": 25, "otherNumAtRisk": 103}, {"id": "EG002", "title": "CKD Patients: Enalapril", "description": "Chronic kidney disease (CKD) patients assigned to enalapril in the core study received enalapril and valsartan placebo in the extension: Enalapril (10, 20, 40, weight stratified) and matching placebo to valsartan (80, 160, 320 mg). All study medications were taken orally once daily, at approximately the same time each day, with or without food.", "seriousNumAffected": 0, "seriousNumAtRisk": 17, "otherNumAffected": 11, "otherNumAtRisk": 17}, {"id": "EG003", "title": "Non-CKD Patients: Enalapril", "description": "Non-chronic kidney disease (CKD) patients assigned to enalapril in the core study continued their enalapril monotherapy treatment in the extension: Enalapril (10, 20, 40, weight stratified)+valsartan placebo. All study medications were taken orally once daily, at approximately the same time each day, with or without food.", "seriousNumAffected": 2, "seriousNumAtRisk": 109, "otherNumAffected": 42, "otherNumAtRisk": 109}], "seriousEvents": [{"term": "Adrenogenital syndrome", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Kidney transplant rejection", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "White blood cell count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Synostosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}], "otherEvents": [{"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 109}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 109}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 109}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 4, "numAtRisk": 109}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 9, "numAtRisk": 109}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 109}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 109}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 109}]}, {"term": "Hypertriglyceridaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 16, "numAtRisk": 109}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 109}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 21}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 103}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 17}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 109}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Study was prolonged from 14 to 66 wks for CKD patients only. Most CKD patients completed the initial 14 wk extension period prior to amendment approval and the study was terminated prematurely with 3 CKD patients progressing to a maximum of Visit 13."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M10698", "name": "Kidney Diseases", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "D000004656", "term": "Enalapril"}, {"id": "D000015773", "term": "Enalaprilat"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M7822", "name": "Enalapril", "asFound": "Box", "relevance": "HIGH"}, {"id": "M18330", "name": "Enalaprilat", "asFound": "Box", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}